Germany · Delayed Price · Currency is EUR Merus Company Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1.
The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors.
In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
| Country | Netherlands |
| Founded | 2003 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 321 |
| CEO | Sven Lundberg |
Contact Details
Address: Uppsalalaan 17 Utrecht, 3584 CT Netherlands | |
| Phone | 31 30 253 8800 |
| Website | merus.nl |
Stock Details
| Ticker Symbol | 2GH |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sven Lundberg | Chief Executive Officer |
| Gregory Perry | Chief Financial Officer |
| Peter Silverman | Chief Operating Officer |
| Sherri Spear | Head of Investor Relations |